Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study

Lauro, Luigi Di; Pizzuti, Laura; Barba, Maddalena; Sergi, Domenico; Sperduti, Isabella; Mottolese, Marcella; Medico, Pietro Del; Belli, F.; Vici, Patrizia; Maria, Ruggero De; Maugeri‐Saccà, Marcello

doi:10.1186/s13046-015-0143-8

Cited by 19 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This approach is indeed intended to postpone chemotherapy, gaining a therapeutic line. Indeed, we must carefully consider all the harm correlated with chemotherapy in an elderly population, along with the scattered information we have on its safety and efficacy [59]. For instance, it might be considered when there is no need for achieving a quick disease control and a rapid tumor regression.…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

Androgen receptor and antiandrogen therapy in male breast cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

Cancers arising in the male breast are uncommon. Male breast cancer is a hormone-driven disease that often expresses the estrogen receptor, and antiestrogen therapy represents the mainstay of treatment. Paradoxically, the advent of a wave of antiestrogens eclipsed the therapeutic potential of alternative therapeutic options. At the beginning of the hormonal therapy era the administration of antiandrogens to metastatic male breast cancer patients was proposed. Ever since the use of these compounds has largely been neglected. A therapeutic role for antiandrogens has been envisioned again in recent years. First, molecular characterization efforts pointed to the androgen receptor as a potential therapeutic target. Second, the development of aromatase inhibitors unexpectedly raised the need for neutralizing androgens in order to tackle endocrine feedback mechanisms responsible for acquired resistance. We herein provide an overview of molecular studies where the androgen receptor was investigated at the genomic, transcriptomic or phenotypic level. We then discuss androgens in the context of the endocrine networks nourishing male breast cancer. Finally, clinical evidence on antiandrogens is summarized along with strategies should be implemented to improve the medical management of these patients.

show abstract

Section: Discussion and Future Directionsmentioning

confidence: 99%

Androgen receptor and antiandrogen therapy in male breast cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Metastasis is identified at diagnosis in approximately 5-15% of MBC cases. Di Lauro et al (94) reported that the most frequent location for metastasis visceral in 76% (lung, liver), bones in 20% and soft tissue (skin) in 4% of the cases in their series of 50 male breast cancer cases. For treating metastatic diseases orchiectomy, adrenalectomy and hypophysectomy have been performed in the past.…”

Section: Treatment For Advanced Diseasementioning

confidence: 96%

Male Breast Cancer

Yalaza¹,

2016

View full text Add to dashboard Cite

IntroductionOver the past two decades, major improvements have been achieved in the understanding of breast cancer, and cure can be offered if the disease is diagnosed at an early stage. However, the disease is more often diagnosed at more advanced stages (3 or 4) in men, in contrast to women. Its rarity among men as well as lack of awareness leads to its detection at later stages. Randomized studies cannot be carried on due to the low incidence of breast cancer in males, with only a few published prospective therapeutic studies in the literature. While the information on male breast cancer (MBC) was obtained from retrospective studies, the recommendations for treatment were derived from studies conducted on female breast cancer (1). This review presents the frequency, etiology, clinical-pathological characteristics and treatment approaches for the rare MBC. Epidemiology-EtiologyMale breast cancer is rare and constitutes 0.5-1% of all patients with breast cancer. The reason of the low incidence rate in men is the relatively low amount of breast tissue along with the difference in their hormonal environment. Even though breast tissue is less in men as compared to women, the factors that influence malignant changes are similar. The Surveillance, Epidemiology and End Result (SEER) Program reported that the incidence of breast cancer was highest at ages 52-71 during 1973-2000, whereas the peak incidence in males was 71 years (2). In fact, some authors state that MBC imitate the behavioral pattern of post-menopausal female breast cancer. The incidence of breast cancer in males and females has increased in the past 25 years. International Association of Cancer Registries (IACR) emphasized this increase and stated that the incidence of female breast cancer increased by 20%, while breast cancer-related deaths increased by 14%. The SEER data also showed that the rate that was 1.1 for 100.000 men in the mid-1970s and raised to 1.44 for 100.000 men by 2010 (3). In USA, 2240 men were diagnosed with breast cancer within the year 2013. The lifetime rate of diagnosis with male breast cancer is 1 in 1000. According to the IACR Turkey data, 0.37% of all cancer types among males are breast cancer (4, 5). IACR has published its new cancer estimates for the year 2012. The most recent cancer estimates for 28 cancer types in 184 countries, which record cancer data, have been made available for users on the GLOBOCAN 2012 website (6).The rate of presentation with advanced stage breast cancer has been decreasing in men. As a matter of fact, a study conducted in 1995 reported the rate of Stage 1-2 disease on diagnosis as 70%, whereas it was reported as 67% in 2010 and 82% in 2015 (7-9). MBC constitutes less than 1% of male cancers and it has a varying rate of incidence across different geographies and ethnic groups (10, 11). Its annual prevalence in Europe is 1 in 10.000 men and these cases constitute less than 1% of all patients with breast cancer (4). However, this rate is above 6% in Central African countries (12). This relatively hig...

show abstract

“…A história natural do câncer, muitas vezes por mudanças de cunho adaptativo que surgem após o uso prolongado de determinadas drogas, tornam as células cancerígenas resistentes e independentes de estímulos hormonais, assim sendo necessária considerar o uso de quimioterápicos 28 .…”

Section: Aspectos Terapêuticos E Prognósticounclassified

“…Dessa forma, no tratamento da doença em questão, visa-se retardar o início da quimioterapia o máximo possível, com o uso da terapia hormonal, já que existe uma grande variedade de tratamentos hormonais disponíveis, e a quimioterapia é menos eficaz em tumores com resposta endócrina positiva 28 .…”

Section: Aspectos Terapêuticos E Prognósticounclassified

See 1 more Smart Citation

Câncer de mama em homens

Araújo

Leite

Amorim

et al. 2019

RIB

View full text Add to dashboard Cite

A neoplasia mamária masculina é rara, representando menos de 1% dos casos de câncer de mama, mas têm incidência crescente ultimamente. Seu manejo guia-se pelos estudos do acometimento feminino, contudo, dados mostram que existem características específicas ao homem. Essa revisão de literatura objetivou ampliar a compreensão dos conhecimentos que abordam o carcinoma masculino, um assunto pouco retratado. As buscas sobre o tema foram feitas nos bancos de dados BIREME, SciELO, MS, Medline, LILACS, PubMed e INCA nos últimos 18 anos. Os resultados mostraram que a patologia apresenta etiologia desconhecida, mas, fatores genéticos (mutações nos genes BRCA1/BRCA2), hormonais e ambientais estão associados com seu maior desenvolvimento. O subtipo mais observado é o carcinoma ductal, e, raramente, o lobular. Manifesta-se por meio de nódulo palpável, indolor, ulceração, retração ou descarga papilar, com mamilo envolvido inicialmente. O diagnóstico baseia-se na história clínica, seguida de mamografia, ultrassonografia e anatomopatológico. Já o estadiamento apresenta limitações quando comparado às mulheres. A terapia inicialmente é cirúrgica, com ressecção completa do tecido mamário, mamilo e esvaziamento axilar. A quimioterapia, radioterapia e a hormonioterapia não são bem estudadas, mas, devido a maior positividade para os receptores hormonais, o tratamento hormonal tem sido de escolha na terapia adjuvante. Apresenta um pior prognóstico quando comparado ao acometimento feminino, pelo diagnóstico tardio, pouco conhecimento da patologia e características específicas masculinas. Conclui-se que são necessários mais estudos para conhecer a neoplasia, para realização de terapias voltadas as suas especificidades, já que é tipicamente conduzida de acordo com as diretrizes do carcinoma feminino. Palavras-Chave: Neoplasia mamária no homem. Câncer de mama masculino. Epidemiologia. Apresentação clínica. Diagnóstico. Tratamento.

show abstract

Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study

Cited by 19 publications

References 22 publications

Androgen receptor and antiandrogen therapy in male breast cancer

Androgen receptor and antiandrogen therapy in male breast cancer

Male Breast Cancer

Câncer de mama em homens

Contact Info

Product

Resources

About